Evidence map›Paper›PMID 34532140›Full record

ArticleJournal of gastrointestinal oncology2021

A

Zhiyu Wang, Wenwen Li, Yaning Wei, Lin An, Shenyong Su, Chenglin Xi, Kunjie Wang, Dan Hong, Yan Shi

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Zhiyu WangDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Wenwen LiDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Yaning WeiDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Lin AnDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Shenyong SuDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Chenglin XiDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Kunjie WangDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Dan HongDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Yan ShiDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Affiliated Hospital of Hebei University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Duodenal adenocarcinoma (DA) is a subtype of small bowel adenocarcinoma (SBA). Compared with gastrointestinal cancers such as colorectal cancer and gastric cancer, SBA is less common. For patients with advanced and metastatic DA, chemotherapies are usually extrapolated from colorectal cancer and gastric cancer but the therapeutic effects remain undefined. Herein, we reported a 50-year-old female patient whom was diagnosed as stage IV DA with metastasis to both lungs and retroperitoneal lymph nodes. The next generation sequencing (NGS) using a panel consisting of 168 cancer related genes revealed amplification of the

Indexed as

case reportduodenal adenocarcinomaSmall bowel cancersystemic therapytrastuzumab

Identifiers

PMID34532140
PMCPMC8421918
OpenAlexW3191756788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.